English

Novo Nordisk

Health news

Novo Nordisk joins forces with OpenAI to fast-track drug research

ADVERTISEMENT

ADVERTISEMENT

Business

Pharma market shake-up: Bayer jumps, Novo Nordisk sinks 10%

Shares of Danish pharmaceutical giant Novo Nordisk fell sharply after its Alzheimer's drug failed to slow progression of the disease in a trial. Meanwhile, Germany's Bayer said their stroke-prevention drug showed positive results, pushing the share price through the roof.

Business

Markets exhale as Novo Nordisk withdraws from Metsera bidding war

Equity markets delivered a mixed response after Pfizer won the bidding war for anti-obesity drugmaker Metsera, as Metsera’s shares slipped but Novo Nordisk’s stock rose on news it was bowing out of the race.

Healthcare

Anti-obesity drugs boost heart health beyond weight loss, study finds

The findings suggest weight loss drugs independently affect heart health risks, researchers said.

Healthcare

Half of people on weight loss drugs quit within one year, study finds

People on weight loss medications such as Ozempic and Wegovy were more likely to stop taking the drugs if they were younger, lived in poorer areas, or were men.

ADVERTISEMENT

Business

Novo Nordisk to cut 9,000 jobs as Eli Lilly competition intensifies

The pharmaceutical giant will axe over 11% of its global workforce as rival Eli Lilly gathers market share in the obesity drug market.

Economy

The Ozempic ripple: When a single jab moves an entire market

As GLP-1 use spreads, grocers and restaurants see lighter baskets, airlines predict fuel savings and health systems eye lower costs—while Denmark sees a clipped GDP.

Markets

European stock markets are up, Novo Nordisk is among the winners

The major European stock indexes started the week in a positive mood, boosted by good news from the defence and pharmaceutical sectors. Meanwhile, new questions on Trump's tariffs are keeping traders around the world on edge.

Markets

Novo Nordisk keeps growing, fuelling hopes of a stock rebound

Novo Nordisk reported 18% sales growth in the first half of 2025, despite a profit warning that triggered a record share drop. Goldman Sachs says the sell-off is overdone and analysts highlight a potential buying opportunity.

Markets

Novo Nordisk shares plummet over 20% on weight-loss drug sale slump

The firm also named Maziar Mike Doustdar as its new CEO on Tuesday, after a gloomy financial forecast spooked investors.

Healthcare

Why Spain thinks Novo Nordisk may be illegally advertising Ozempic

Spain is investigating Novo Nordisk over concerns it may be indirectly marketing its weight loss drugs. Euronews Health spoke to the country’s health secretary to find out more.

Health news

Novo Nordisk CEO steps down amid competition for weight loss drugs

Lars Fruergaard Jørgensen, who has led the pharmaceutical giant since 2017, joined the firm in 1991.

Business

Novo Nordisk cuts forecast as weight-loss drug competition heats up

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth outlook for 2025 amid intensifying competition in the weight-loss drug markets.

Healthcare

Weight-loss drugs could treat patients with serious liver condition

There are currently no drugs approved in the European Union to treat the liver condition known as MASH, but a new trial of semaglutide has shown “exciting” results.

Business

New tariffs from the US are about to hit the pharmaceutical sector

Despite sparking global-market turmoil with last week’s announcement, the US President is promising new tariffs, now targeting the previously exempted pharmaceutical sector.

Markets

Novo Nordisk shares post the biggest monthly decline since 2002

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several disappointing trial results. However, analysts remain optimistic about the shares, forecasting a potential price upside of up to 60% over the next 12 months.

Business

SAP overtook Novo Nordisk to become Europe's most valuable company

The German software company's share price gained 40% in the past year, while Danish drugmaker Novo Nordisk has gradually lost almost half of its own since last summer.